JPWO2021043870A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021043870A5 JPWO2021043870A5 JP2022514513A JP2022514513A JPWO2021043870A5 JP WO2021043870 A5 JPWO2021043870 A5 JP WO2021043870A5 JP 2022514513 A JP2022514513 A JP 2022514513A JP 2022514513 A JP2022514513 A JP 2022514513A JP WO2021043870 A5 JPWO2021043870 A5 JP WO2021043870A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancer
- deficiency
- tautomer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1912674.7A GB201912674D0 (en) | 2019-09-04 | 2019-09-04 | Novel compounds |
| GB1912674.7 | 2019-09-04 | ||
| PCT/EP2020/074540 WO2021043870A1 (en) | 2019-09-04 | 2020-09-03 | Substituted cyanopyrrolidines with activity as usp30 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546717A JP2022546717A (ja) | 2022-11-07 |
| JPWO2021043870A5 true JPWO2021043870A5 (https=) | 2023-09-11 |
| JP2022546717A5 JP2022546717A5 (https=) | 2023-09-11 |
Family
ID=68207049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514513A Ceased JP2022546717A (ja) | 2019-09-04 | 2020-09-03 | Ｕｓｐ３０阻害剤としての活性を有する置換シアノピロリジン類 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220315572A1 (https=) |
| EP (1) | EP4025573B9 (https=) |
| JP (1) | JP2022546717A (https=) |
| KR (1) | KR20220054867A (https=) |
| CN (1) | CN114341133B (https=) |
| AU (1) | AU2020340527A1 (https=) |
| BR (1) | BR112022003527A2 (https=) |
| CA (1) | CA3146040A1 (https=) |
| CO (1) | CO2022003608A2 (https=) |
| GB (1) | GB201912674D0 (https=) |
| IL (1) | IL290929B2 (https=) |
| MX (1) | MX2022002686A (https=) |
| WO (1) | WO2021043870A1 (https=) |
| ZA (1) | ZA202203775B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| LT3860989T (lt) * | 2018-10-05 | 2023-06-12 | Forma Therapeutics, Inc. | Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai |
| WO2021204856A1 (en) | 2020-04-08 | 2021-10-14 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| IL298526A (en) | 2020-05-28 | 2023-01-01 | Mission Therapeutics Ltd | N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction |
| BR112022019722A2 (pt) | 2020-06-04 | 2022-12-20 | Mission Therapeutics Ltd | N-cianopirrolidinas com atividade como inibidores de usp30 |
| DK4161929T3 (da) | 2020-06-08 | 2025-08-18 | Mission Therapeutics Ltd | 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| US20250034122A1 (en) | 2021-12-01 | 2025-01-30 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| KR20240132148A (ko) * | 2023-02-24 | 2024-09-03 | 연세대학교 산학협력단 | 인덴 유도체를 유효성분으로 포함하는 섬유화의 예방 또는 치료용 조성물 |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2001077073A1 (en) | 2000-04-06 | 2001-10-18 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| WO2007119214A2 (en) | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| US8242271B2 (en) | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| PE20090606A1 (es) | 2007-08-20 | 2009-06-17 | Glaxo Group Ltd | Nuevos inhibidores de catepsina c y uso |
| PE20091843A1 (es) | 2008-04-18 | 2010-01-07 | Glaxo Group Ltd | Inhibidores de catepsina c |
| TW201002318A (en) | 2008-04-18 | 2010-01-16 | Glaxo Group Ltd | Cathepsin C inhibitors |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| CA2918242C (en) | 2013-07-31 | 2022-06-21 | Merck Patent Gmbh | Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof |
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| WO2015183987A1 (en) | 2014-05-27 | 2015-12-03 | Pharmakea, Inc. | Compositions and methods of delivery of deubiquitinase inhibitors |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| CA2960277A1 (en) * | 2014-09-10 | 2016-03-17 | Epizyme, Inc. | Substituted pyrrolidine carboxamide compounds |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| MX373656B (es) * | 2015-03-30 | 2020-04-02 | Mission Therapeutics Ltd | Compuestos de 1-ciano-pirrolidina como inhibidores de las enzimas desubiquitinantes, como la hidrolasa 30 de la c-terminal de la ubiquitina (usp30), y el uso de los mismos en el tratamiento de condiciones de disfunción mitocondrial y tratamiento de cancér. |
| US10669234B2 (en) | 2015-07-14 | 2020-06-02 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| JP6959252B2 (ja) * | 2016-03-24 | 2021-11-02 | ミッション セラピューティクス リミティド | Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体 |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
| BR112020003725A2 (pt) | 2017-10-06 | 2020-11-03 | Forma Therapeutics, Inc. | inibição da peptidase 30 específica de ubiquitina |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| JP7434285B2 (ja) | 2018-08-14 | 2024-02-20 | アムジエン・インコーポレーテツド | Ｎ－シアノ－７－アザノルボルナン誘導体及びその使用 |
| LT3860989T (lt) | 2018-10-05 | 2023-06-12 | Forma Therapeutics, Inc. | Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai |
| IL298526A (en) * | 2020-05-28 | 2023-01-01 | Mission Therapeutics Ltd | N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction |
-
2019
- 2019-09-04 GB GBGB1912674.7A patent/GB201912674D0/en not_active Ceased
-
2020
- 2020-09-03 WO PCT/EP2020/074540 patent/WO2021043870A1/en not_active Ceased
- 2020-09-03 BR BR112022003527A patent/BR112022003527A2/pt unknown
- 2020-09-03 JP JP2022514513A patent/JP2022546717A/ja not_active Ceased
- 2020-09-03 KR KR1020227010882A patent/KR20220054867A/ko not_active Withdrawn
- 2020-09-03 MX MX2022002686A patent/MX2022002686A/es unknown
- 2020-09-03 IL IL290929A patent/IL290929B2/en unknown
- 2020-09-03 CA CA3146040A patent/CA3146040A1/en active Pending
- 2020-09-03 AU AU2020340527A patent/AU2020340527A1/en active Pending
- 2020-09-03 EP EP20771779.4A patent/EP4025573B9/en active Active
- 2020-09-03 CN CN202080061743.3A patent/CN114341133B/zh active Active
- 2020-09-03 US US17/639,015 patent/US20220315572A1/en not_active Abandoned
-
2022
- 2022-03-25 CO CONC2022/0003608A patent/CO2022003608A2/es unknown
- 2022-04-01 ZA ZA2022/03775A patent/ZA202203775B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021043870A5 (https=) | ||
| HRP20250891T1 (hr) | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primjenu u liječenju mitohondrijske disfunkcije, raka i fibroze | |
| JP2020521730A5 (https=) | ||
| US12152023B2 (en) | Compositions, formulations and methods for treating ocular diseases | |
| AP813A (en) | Urea derivatives as inhibitors of IMPDH enzyme. | |
| JP2019533659A5 (https=) | ||
| JP2019501142A5 (https=) | ||
| US6344465B1 (en) | Inhibitors of IMPDH enzyme | |
| JP2019504009A5 (https=) | ||
| US9174950B2 (en) | Compounds, compositions, and methods for preventing metastasis of cancer cells | |
| JP2019503362A5 (https=) | ||
| US8883832B2 (en) | Compounds, compositions, and methods for preventing metastasis of cancer cells | |
| EP2699557B1 (en) | 3-(oxazol-2-yl-ethoxy)- and 3-(thiazol-2-yl-ethoxy)-benzamide derivatives as anti-bacterial agents | |
| US6960605B2 (en) | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging | |
| JP2016512844A5 (https=) | ||
| JP2020524166A5 (https=) | ||
| JP2019513135A5 (https=) | ||
| JP2020512298A5 (https=) | ||
| WO2010115836A4 (en) | Substituted piperidines as ccr3 antagonists | |
| JP2023126245A5 (https=) | ||
| WO2015069810A1 (en) | Treatment of cardiac remodeling and other heart conditions | |
| JPWO2021239863A5 (https=) | ||
| JPWO2021204856A5 (https=) | ||
| JPWO2021249909A5 (https=) | ||
| JPWO2021245186A5 (https=) |